Shenzhen BioX Medical Co., Ltd. stands as a titan in the development of molecular diagnostic analysis systems and genetic testing solutions. Founded in 2017 in Shenzhen—the "Silicon Valley of Hardware"—we have successfully expanded our footprint to serve as a premier supplier of precision medicine platforms in Moscow and the broader CIS region.
Our facility spans over 9,000 square meters, staffed by a multidisciplinary team of 200+ specialists. We don't just manufacture hardware; we engineer ecosystems. By integrating advanced automation with diagnostic accuracy, we empower Moscow’s clinical laboratories and research institutions to achieve breakthrough results in oncology, pathogen detection, and biomarker analysis.
Moscow has emerged as a global leader in medical digitalization. With the Skolkovo Innovation Center and the Moscow Health Department (UMIaS), the demand for precision medicine platforms that support high-throughput genetic sequencing and automated PCR workflows is at an all-time high. Our platforms are designed to integrate seamlessly with Moscow's sophisticated laboratory information systems (LIS).
Navigating the Roszdravnadzor (Russian Federal Service for Surveillance in Healthcare) requirements is critical. BioX Medical ensures that all platforms provided in the Moscow region meet stringent local electrical safety, biological compatibility, and diagnostic efficacy standards, ensuring a smooth path to clinical implementation.
We recognize that precision equipment requires precision support. Our Moscow-based partners provide on-site calibration, maintenance, and technical training in Russian, ensuring that downtime is minimized in critical healthcare environments like the Moscow International Medical Cluster.
The global precision medicine market is shifting from "one-size-fits-all" treatments to personalized therapeutic interventions. This transition is powered by hardware that can detect single-nucleotide polymorphisms (SNPs) and complex biomarkers with 99.9% repeatability.
From the genomic hubs of Boston and Shanghai to the clinical centers in Moscow, BioX Medical is at the forefront of this evolution. Our platforms utilize microfluidic technology and AI-driven thermal regulation to ensure that molecular samples remain stable under diverse environmental conditions—a critical feature for the varying climates of the Russian Federation.
Reducing manual pipette errors through robotic nucleic acid extraction and automated liquid handling.
Real-time data analysis where the diagnostic platform suggests clinical pathways based on detected mutations.
Point-of-care (POC) precision platforms that bring the power of a central Moscow lab to remote clinics.
As we look toward 2025-2030, BioX Medical is focusing on Quantum Diagnostics Integration and Multi-Omics Platforms. We are actively seeking collaboration with Moscow-based scientific institutes to co-develop platforms that can analyze DNA, RNA, proteins, and metabolites simultaneously on a single automated footprint.
Whether you are establishing a new genomics lab in Skolkovo or upgrading a clinical facility in central Moscow, BioX Medical provides the precision engineering and local support necessary for your success.
Get a Customized Quote for Your Project
BioX Medical
